Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

被引：9

作者：

Kahraman, Seda ^{[1
]}

Erul, Enes ^{[2
]}

Seyyar, Mustafa ^{[3
]}

Gumusay, Ozge ^{[4
]}

Bayram, Ertugrul ^{[5
]}

Demirel, Burcin Cakan ^{[6
]}

Acar, Omer ^{[7
]}

Aksoy, Sercan ^{[2
]}

Baytemur, Naziyet Kose ^{[8
]}

Sahin, Elif ^{[3
]}

Cabuk, Devrim ^{[3
]}

Basaran, Gul ^{[4
]}

Paydas, Semra ^{[5
]}

Yaren, Arzu ^{[6
]}

Guven, Deniz Can ^{[2
]}

Erdogan, Atike Pinar ^{[7
]}

Demirci, Umut ^{[8
]}

Yasar, Alper ^{[9
]}

Bayoglu, Ibrahim Vedat ^{[9
]}

Hizal, Mutlu ^{[1
]}

Gulbagci, Burcu ^{[10
]}

Paksoy, Nail ^{[11
]}

Davarci, Sena Ece ^{[12
]}

Yilmaz, Funda ^{[13
]}

Dogan, Ozlem ^{[14
]}

Orhan, Sibel Oyucu ^{[15
]}

Kayikcioglu, Erkan ^{[16
]}

Aytac, Ali ^{[17
]}

Keskinkilic, Merve ^{[18
]}

Mocan, Eda Eylemer ^{[19
]}

Unal, Olcun Umit ^{[20
]}

Aydin, Esra ^{[21
]}

Yucel, Hakan ^{[22
]}

Isik, Deniz ^{[23
]}

Eren, Onder ^{[24
]}

Uluc, Basak Oyan ^{[4
]}

Ozcelik, Melike ^{[25
]}

Hacibekiroglu, Ilhan ^{[10
]}

Aydiner, Adnan ^{[11
]}

Demir, Hacer ^{[12
]}

Oksuzoglu, Berna ^{[13
]}

Cilbir, Ebru ^{[14
]}

Cubukcu, Erdem ^{[15
]}

Cetin, Bulent ^{[16
]}

Oktay, Esin ^{[17
]}

Erol, Cihan ^{[1
]}

Okutur, Sadi Kerem ^{[26
]}

Yildirim, Nilgun ^{[27
]}

Alkan, Ali ^{[28
]}

Selcukbiricik, Fatih ^{[29
]}

机构：

[1] Ankara Yildirim Beyazit Univ, Ankara City Hosp, Dept Med Oncol, TR-06800 Ankara, Turkiye

[2] Hacettepe Univ, Canc Inst, Dept Med Oncol, TR-06590 Ankara, Turkiye

[3] Kocaeli Univ, Med Fac Hosp, Dept Med Oncol, TR-41000 Kocaeli, Turkiye

[4] Acibadem Univ, Sch Med, Dept Med Oncol, TR-34750 Istanbul, Turkiye

[5] Cukurova Univ, Dept Med Oncol, TR-01330 Adana, Turkiye

[6] Pamukkale Univ Hosp, Dept Med Oncol, TR-20160 Denizli, Turkiye

[7] Manisa Celal Bayar Univ Hosp, Dept Med Oncol, TR-45120 Mersin, Turkiye

[8] Ankara Mem Hosp, Dept Med Oncol, TR-06520 Ankara, Turkiye

[9] Marmara Univ, Dept Med Oncol, Pendik Res & Applicat Hosp, TR-34899 Istanbul, Turkiye

[10] Sakarya Univ, Sch Med, Dept Med Oncol, TR-54187 Sakarya, Turkiye

[11] Istanbul Univ, Dept Med Oncol, TR-34093 Istanbul, Turkiye

[12] Afyonkarahisar Hlth Sci Univ, Dept Med Oncol, TR-03200 Afyonkarahisar, Turkiye

[13] Dr Abdurrahman Yurtaslan Ankara Oncol Training & R, Dept Med Oncol, TR-06200 Ankara, Turkiye

[14] Ankara Etlik City Hosp, Dept Med Oncol, TR-06170 Ankara, Turkiye

[15] Uludag Univ, Dept Med Oncol, TR-16059 Bursa, Turkiye

[16] Suleyman Demirel Univ, Dept Med Oncol, TR-32260 Isparta, Turkiye

[17] Aydin Adnan Menderes Univ, Dept Med Oncol, Training & Res Hosp, TR-09100 Aydin, Turkiye

[18] Dokuz Eylul Univ, Res & Applicat Hosp, Dept Med Oncol, TR-35340 Izmir, Turkiye

[19] Ankara Univ, Dept Med Oncol, TR-06080 Ankara, Turkiye

[20] Tepecik Training & Res Hosp, Dept Med Oncol, TR-35180 Izmir, Turkiye

[21] Recep Tayyip Erdogan Univ Training & Res Hosp, Dept Med Oncol, TR-53020 Rize, Turkiye

[22] Gaziantep Univ, Dept Med Oncol, TR-27580 Gaziantep, Turkiye

[23] Kocaeli Med Pk Hosp, Dept Med Oncol, TR-41140 Kocaeli, Turkiye

[24] Selcuk Univ, Dept Med Oncol, Med Fac Hosp, TR-42250 Konya, Turkiye

[25] Umraniye Training & Res Hosp, Dept Med Oncol, TR-34764 Istanbul, Turkiye

[26] Istanbul Arel Univ, Bahcelievler Mem Hosp, Dept Med Oncol, TR-34537 Istanbul, Turkiye

[27] Firat Univ Hosp, Dept Med Oncol, TR-23200 Elazig, Turkiye

[28] Mugla Sitki Kocman Univ Training & Res Hosp, Dept Med Oncol, TR-48000 Mugla, Turkiye

[29] Koc Univ Hosp, Dept Med Oncol, TR-34010 Istanbul, Turkiye

[30] Elazig Fethi Sekin City Hosp, Dept Med Oncol, TR-23280 Elazig, Turkiye

[31] Acibadem Bodrum Hosp, Dept Med Oncol, TR-48420 Mugla, Turkiye

[32] Canakkale Onsekiz Mart Univ, Dept Med Oncol, Res & Practice Hosp, TR-17100 Canakkale, Turkiye

[33] Adana City Training & Res Hosp, Dept Med Oncol, TR-01230 Adana, Turkiye

[34] Kocaeli Derince Training & Res Hosp, Dept Med Oncol, TR-41310 Kocaeli, Turkiye

[35] Kahramanmaras Necip Fazil City Hosp, Dept Med Oncol, TR-46050 Kahramanmaras, Turkiye

[36] Necmettin Erbakan Univ, Dept Med Oncol, Meram Med Fac Hosp, TR-42080 Konya, Turkiye

[37] Gulhane Training & Res Hosp, Dept Med Oncol, TR-06010 Ankara, Turkiye

[38] Mersin City Hosp, Dept Med Oncol, TR-96015 Mersin, Turkiye

[39] Namik Kemal Univ, Dept Med Oncol, Hlth Applicat & Res Hosp, TR-59030 Tekirdag, Turkiye

[40] Van Yuzuncu Yil Univ, Dursun Odabas Hosp, Dept Med Oncol, TR-65090 Van, Turkiye

[41] Manisa City Hosp, Dept Med Oncol, TR-45040 Manisa, Turkiye

[42] Konya City Hosp, Dept Med Oncol, TR-42020 Konya, Turkiye

[43] Ordu State Hosp, Dept Med Oncol, TR-52200 Ordu, Turkiye

[44] Aydin Ataturk State Hosp, Dept Med Oncol, TR-09020 Aydin, Turkiye

[45] Izmir Bozyaka Training & Res Hosp, Dept Med Oncol, TR-35170 Izmir, Turkiye

[46] Anadolu Med Ctr, Dept Med Oncol, TR-34758 Istanbul, Turkiye

来源：

FUTURE ONCOLOGY | 2023年

关键词：

CDK; 4; 6; inhibitors; HER2-negative metastatic breast cancer; HR-positive; letrozole;

D O I：

10.2217/fon-2022-1287

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.

引用

页码：727 / 736

页数：10

共 50 条

[41] Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant
Malorni, Luca
Tyekucheva, Svitlana'
Hilbers, Florentine S.
Ignatiadis, Michail
Neven, Patrick
Colleoni, Marco
Henry, Stephanie
Ballestrero, Alberto
Bonetti, Andrea
Jerusalem, Guy
Papadimitriou, Konstantinos
Bernardo, Antonio
Seles, Elena
Duhoux, Francois P.
MacPherson, Iain R.
Thomson, Alastair
Davies, David Mark
Bergqvist, Mattias
Migliaccio, Ilenia
Gebhart, Geraldine
Zoppoli, Gabriele
Bliss, Judith M.
Benelli, Matteo
McCartney, Amelia
Kammler, Roswitha
De Swert, Heidi
Ruepp, Barbara
Fumagalli, Debora
Maibach, Rudolf
Cameron, David
Loi, Sherene
Piccart, Martine
Regan, Meredith M.
EUROPEAN JOURNAL OF CANCER, 2022, 164 : 39 - 51
[42] Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series
Schettini, Francesco
De Santo, Irene
Rea, Carmen G.
Viggiani, Martina
Buono, Giuseppe
De Angelis, Carmine
Cardalesi, Cinzia
Lauria, Rossella
Giuliano, Mario
Forestieri, Valeria
Thomas, Guglielmo
Maione, Pierfrancesco
Limite, Gennaro
Accurso, Antonello
Malorni, Luca
De Placido, Sabino
Arpino, Grazia
MOLECULAR AND CLINICAL ONCOLOGY, 2020, 12 (05) : 456 - 460
[43] Abemaciclib with or without fulvestrant for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with disease progression following prior treatment with palbociclib.
Tamragouri, Keerthi
Cobleigh, Melody A.
Rao, Ruta D.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[44] Health-related quality of life (HRQoL) in hormone receptor-positive, HER2-negative, luminal B breast cancer patients treated with ribociclib plus letrozole or chemotherapy
Villacampa, Guillermo
Pare, Laia
Hernando, Cristina
Arumi, Miriam
Munoz, Montserrat
Gil-Gil, Miguel
Izarzugaza, Yann
Ferrer, Neus
Montano, Alvaro
Ciruelos, Eva
Gonzalez-Santiago, Santiago
Falato, Claudette
Villagrasa, Patricia
Gavila, Joaquin
Prat, Aleix
Pascual, Tomas
CANCER RESEARCH, 2022, 82 (04)
[45] Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer
Pauline du Rusquec
Clément Palpacuer
Loic Campion
Anne Patsouris
Paule Augereau
Carole Gourmelon
Marie Robert
Laurence Dumas
Folliard Caroline
Mario Campone
Jean-Sébastien Frenel
Breast Cancer Research and Treatment, 2018, 168 : 559 - 566
[46] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
Cantini, Luca
Trapani, Dario
Guidi, Lorenzo
Bielo, Luca Boscolo
Scafetta, Roberta
Koziej, Marcin
Vidal, Laura
Saini, Kamal S.
Curigliano, Giuseppe
CANCER TREATMENT REVIEWS, 2024, 123
[47] Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer
du Rusquec, Pauline
Palpacuer, Clement
Campion, Loic
Patsouris, Anne
Augereau, Paule
Gourmelon, Carole
Robert, Marie
Dumas, Laurence
Caroline, Folliard
Campone, Mario
Frenel, Jean-Sebastien
BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (02) : 559 - 566
[48] EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
K. Almstedt
S. Mendoza
M. Otto
M. J. Battista
J. Steetskamp
A. S. Heimes
S. Krajnak
A. Poplawski
A. Gerhold-Ay
A. Hasenburg
C. Denkert
M. Schmidt
Breast Cancer Research and Treatment, 2020, 182 : 137 - 146
[49] Molecular classification of hormone receptor-positive HER2-negative breast cancer
Jin, Xi
Zhou, Yi-Fan
Ma, Ding
Zhao, Shen
Lin, Cai-Jin
Xiao, Yi
Fu, Tong
Liu, Cheng-Lin
Chen, Yi-Yu
Xiao, Wen-Xuan
Liu, Ya-Qing
Chen, Qing-Wang
Yu, Ying
Shi, Le-Ming
Shi, Jin-Xiu
Huang, Wei
Robertson, John F. R.
Jiang, Yi-Zhou
Shao, Zhi-Ming
NATURE GENETICS, 2023, 55 (10) : 1696 - +
[50] Management of hormone receptor-positive, HER2-negative early breast cancer
Walsh, Elaine M.
Smith, Karen L.
Stearns, Vered
SEMINARS IN ONCOLOGY, 2020, 47 (04) : 187 - 200

← 1 2 3 4 5 →